13 citations
,
July 2011 in “Journal of Dermatological Treatment” Clobetasol and pimecrolimus are similarly effective for alopecia areata, but pimecrolimus has fewer side effects and is preferred for long-term use.
5 citations
,
June 2012 in “Journal of Cosmetic and Laser Therapy” Finasteride and intense pulsed light effectively reduce unwanted facial hair in women, but may not be cost-effective.
MTX and GC combinations are the most effective for early rheumatoid arthritis.
2 citations
,
March 2015 in “Toxicology and Environmental Health Sciences” Rice bran extract caused moderate skin irritation but no eye irritation, while a diluted essence was not irritating to skin and only slightly to guinea pigs.
2 citations
,
April 2018 in “SLEEP” People with rheumatoid arthritis have poorer sleep quality than healthy individuals.
1 citations
,
September 2019 Managing severe infections in SLE patients requires tailored treatment strategies.
1 citations
,
April 2018 in “Sleep” Finasteride increases risk of sleep apnea and insomnia.
1 citations
,
April 2018 in “SLEEP” People with obstructive sleep apnea are more likely to get herpes zoster, but nightmares don't affect the risk.
1 citations
,
July 2025 in “Journal of Investigative Dermatology” Increasing m6A levels can improve skin cell growth and wound healing.
1 citations
,
July 2025 in “Journal of Investigative Dermatology” 1 citations
,
July 2025 in “Journal of Investigative Dermatology” IL-27 may help prevent hair loss by creating immune-suppressing cells.
1 citations
,
October 2021 in “Journal of Investigative Dermatology”
1 citations
,
April 2019 in “The journal of investigative dermatology/Journal of investigative dermatology” Melanocyte-associated antigens may play a key role in alopecia areata and could be targets for new treatments.
1 citations
,
April 2018 in “Journal of Investigative Dermatology” Simvastatin helps hair regrowth in autoimmune alopecia by directly affecting T cells.
1 citations
,
April 2016 in “Journal of Investigative Dermatology” Targeting specific T cells may help treat alopecia areata.
March 2026 in “The Journal of Sexual Medicine” Hormone therapy can improve sexual health and quality of life for women 70 and older.
November 2025 in “Journal of Investigative Dermatology” Dithranol reduces inflammation in alopecia areata by lowering certain immune responses.
July 2025 in “Journal of Investigative Dermatology” Minoxidil may improve nail growth and appearance.
July 2025 in “Journal of Investigative Dermatology” Immune system changes may contribute to female pattern hair loss.
July 2025 in “Journal of Investigative Dermatology” Solid Lipid Particle technology makes retinol more stable, effective, and gentle on the skin.
July 2025 in “Journal of Investigative Dermatology” Researchers created long-lasting, diverse skin organoids from mouse hair follicle stem cells, useful for studying skin.
July 2025 in “Journal of Investigative Dermatology” Systemic therapy may reduce male infertility in psoriasis patients.
July 2025 in “Journal of Investigative Dermatology” Topical minoxidil is dangerous for cats and dogs.
July 2025 in “Journal of Investigative Dermatology” Tissue-engineered skin substitutes can model junctional epidermolysis bullosa and may help develop gene therapy.
July 2025 in “Journal of Investigative Dermatology” Negative Pressure Wound Therapy reduces surgical site infections and speeds up healing.
July 2025 in “Journal of Investigative Dermatology” High-dose UVA-1 therapy improves symptoms and skin condition in sclerosing skin disease.
July 2025 in “Journal of Investigative Dermatology” Leflunomide may reduce the risk of alopecia areata, while methotrexate, cyclosporine, and rituximab may increase it.
July 2024 in “Journal of Investigative Dermatology” Expanding regulatory T cells may help treat alopecia areata by reducing harmful immune cells.
July 2024 in “Journal of Investigative Dermatology” A peptide in shampoo can promote hair growth and improve hair condition.
October 2021 in “Journal of Investigative Dermatology” COVID-19 infection rates were low in patients with immune diseases, regardless of their treatment type.